ClinicalTrials.govrestricted
Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer
ClinicalTrials.gov study NCT00739063. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ShareScore
28/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 12
- Harmonization
- 8
- Access
- 4
- Reuse readiness
- 0
- Engagement
- 4